NASDAQ:CRVS
Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. reported net income of −$15.3M in fiscal 2025. Free cash flow was −$33.0M, and the diluted share count rose 30.8%.Summary generated from Corvus Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−32.6%
Debt / equityn/a
Free cash flow−$33.0M
FCF marginn/a
Share count change+30.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −39 | −33 | −23 | −28 | −43 |
| Net income | −43 | −41 | −27 | −62 | −15 |
| Free cash flow | −37 | −27 | −24 | n/a | −33 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KDirector or officer change
Jul 22, 2026 - 4Insider transaction report
Jun 15, 2026 - 4Insider transaction report
Jun 15, 2026 - 8-KResults of a shareholder vote
Jun 12, 2026 - 8-KRegulation FD disclosure
May 14, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026